LA JOLLA, Calif.–(BUSINESS WIRE)– #ANRE–Arialys Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of ANRE
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
